<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>316</volume><submitter>Filippatos F</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>SARS-CoV-2 Spike protein Receptor Binding Domain neutralizing antibodies (NAbs-RBD) inhibit the viral binding to angiotensin-converting enzyme 2 (ACE2) receptors. We compared an ELISA and a fluorescence immunochromatography (FIC) method in NAbs-RBD detection after COVID-19 immunization.&lt;h4>Method&lt;/h4>Serum samples from healthcare workers (HCWs) vaccinated with BNT162b2 were collected one and four months after the second dose. NAbs-RBD (%) detection was performed using ELISA cPass™ (FDA approved) and FIC n-AbCOVID-19® assays.&lt;h4>Results&lt;/h4>Samples from 200 HCWs [median age (IQR): 45(35-53)] were tested with both assays. There was a good qualitative agreement between the two methods [AUC: 0.92(95%C.I.: 0.89-0.94, P-value:0.007)]. NAbs-RBD (%), one and four months after im</pubmed_abstract><journal>Journal of virological methods</journal><pagination>114728</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10074729</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Comparison of a rapid fluorescence immunochromatographic test with an enzyme-linked immunosorbent assay for measurement of SARS-CoV-2 spike protein antibody neutralizing activity.</pubmed_title><pmcid>PMC10074729</pmcid><pubmed_authors>Michos A</pubmed_authors><pubmed_authors>Filippatos F</pubmed_authors><pubmed_authors>Tatsi EB</pubmed_authors><pubmed_authors>Papagiannopoulos C</pubmed_authors><pubmed_authors>Syriopoulou V</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comparison of a rapid fluorescence immunochromatographic test with an enzyme-linked immunosorbent assay for measurement of SARS-CoV-2 spike protein antibody neutralizing activity.</name><description>&lt;h4>Background&lt;/h4>SARS-CoV-2 Spike protein Receptor Binding Domain neutralizing antibodies (NAbs-RBD) inhibit the viral binding to angiotensin-converting enzyme 2 (ACE2) receptors. We compared an ELISA and a fluorescence immunochromatography (FIC) method in NAbs-RBD detection after COVID-19 immunization.&lt;h4>Method&lt;/h4>Serum samples from healthcare workers (HCWs) vaccinated with BNT162b2 were collected one and four months after the second dose. NAbs-RBD (%) detection was performed using ELISA cPass™ (FDA approved) and FIC n-AbCOVID-19® assays.&lt;h4>Results&lt;/h4>Samples from 200 HCWs [median age (IQR): 45(35-53)] were tested with both assays. There was a good qualitative agreement between the two methods [AUC: 0.92(95%C.I.: 0.89-0.94, P-value:0.007)]. NAbs-RBD (%), one and four months after im</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jun</publication><modification>2025-04-18T16:30:10.487Z</modification><creation>2025-02-19T04:16:18.278Z</creation></dates><accession>S-EPMC10074729</accession><cross_references><pubmed>37028561</pubmed><doi>10.1016/j.jviromet.2023.114728</doi></cross_references></HashMap>